Bevacizumab biosimilar - Centus Biotherapeutics

Drug Profile

Bevacizumab biosimilar - Centus Biotherapeutics

Alternative Names: FKB-238

Latest Information Update: 10 Jul 2017

Price : $50

At a glance

  • Originator Fujifilm Kyowa Kirin Biologics
  • Developer Centus Biotherapeutics
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Pharmacokinetics and adverse events data from a phase I trial in Volunteers presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017 (3247770)
  • 02 Jun 2017 Fujifilm Kyowa Kirin Biologics completes a phase I trial in Healthy volunteers in the United Kingdom
  • 15 Jun 2016 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease) in Spain (IV) (EudraCT2015-004104-33)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top